Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative
Karikari Thomas K; Lantero Rodriguez Juan; Zettergren Anne; Blennow Kaj; Ashton Nicholas J; Lord Jodie; Suárez-Calvet Marc; Zetterberg Henrik; Snellman Anniina; Proitsi Petroula; Benedet Andrea L
Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative
Karikari Thomas K
Lantero Rodriguez Juan
Zettergren Anne
Blennow Kaj
Ashton Nicholas J
Lord Jodie
Suárez-Calvet Marc
Zetterberg Henrik
Snellman Anniina
Proitsi Petroula
Benedet Andrea L
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021042823454
https://urn.fi/URN:NBN:fi-fe2021042823454
Tiivistelmä
Polygenic risk for AD including APOE was found to associate with plasma p-tau181 independent of diagnostic and Aβ pathology status, while polygenic risk for AD beyond APOE was associated with plasma p-tau181 only in MCI and Aβ-positive individuals. These results extend the knowledge about the relation between genetic risk for AD and p-tau181, and further support the usefulness of plasma p-tau181 as a biomarker of AD.\nRecent studies suggest that plasma phosphorylated tau181 (p-tau181) is a highly specific biomarker for Alzheimer's disease (AD)-related tau pathology. It has great potential for the diagnostic and prognostic evaluation of AD, since it identifies AD with the same accuracy as tau PET and CSF p-tau181 and predicts the development of AD dementia in cognitively unimpaired (CU) individuals and in those with mild cognitive impairment (MCI). Plasma p-tau181 may also be used as a biomarker in studies exploring disease pathogenesis, such as genetic or environmental risk factors for AD-type tau pathology. The aim of the present study was to investigate the relation between polygenic risk scores (PRSs) for AD and plasma p-tau181.\nData from the Alzheimer's Disease Neuroimaging Initiative (ADNI) was used to examine the relation between AD PRSs, constructed based on findings in recent genome-wide association studies, and plasma p-tau181, using linear regression models. Analyses were performed in the total sample (n = 818), after stratification on diagnostic status (CU (n = 236), MCI (n = 434), AD dementia (n = 148)), and after stratification on Aβ pathology status (Aβ positives (n = 322), Aβ negatives (n = 409)).\n), while the non-APOE PRSs were associated with plasma p-tau181 in Aβ positives only (p = 0.02).\nCONCLUSIONS\nBACKGROUND\nMETHODS\nRESULTS
Kokoelmat
- Rinnakkaistallenteet [19207]